LONDON (ShareCast) - (Sharecast News) - Spain's Grifols has begun production of its hyperimmune globulin, the first treatment specifically designed for use against SARS-CoV-2.
Manufacture of the treatment, which is derived from the blood plasma of patients who have recovered from the illness has started at the company's Clayton, North Carolina, US, plant.

The first batch of doses within the framework of ongoing clinical trials are expected to be ready in July.

Grifols is working together with America's Food and Drug Administration, National Institutes of Health and the same country's Biomedical Advanced Research and Development Authority, among other institutions.

Under the agreements in place, they will work jointly on preclinical and clinical studies to assess the efficacy of the treatment.

Grifols was also the first company to have begun production of hyperimmune globulin.

Another clinical study was ongoing in Spain into the efficacy of high doses of intravenous globulin to stabilise or improve the condition of patients suffering from Covid-19.

The study was aimed at both assessing the ability of the antibodies to impede human cells from becoming infected and to moderate the immune system's response so as to avoid 'cytokine storm' ailing some patients.

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE